Precision Neonatal Medicine

1. Why Neonates Are a Special Precision Medicine Population

• Physiological immaturity: Drug metabolism, renal clearance, blood-brain barrier function, and receptor expression all change rapidly in the first weeks of life. A "one-size-fits-all" dosing approach is inherently dangerous.
• Genetic disorders manifest early: Many single-gene (Mendelian) disorders, inborn errors of metabolism, and chromosomal conditions present first in the neonatal period and contribute disproportionately to neonatal morbidity and mortality.
• Critical developmental window: Early intervention during this window can prevent irreversible end-organ damage (brain, liver, kidneys), making rapid diagnosis especially high-stakes.
• Limited trial data: Most drugs used in NICUs are prescribed off-label, derived from adult pharmacokinetic data.
• Goldman-Cecil Medicine, p. 131 - notes that rapid genome sequencing (~19.5 hours) is already used to treat patients with undiagnosed and potentially fatal disorders in the neonatal ICU.

2. Genomics - The Engine of Precision Neonatology

Rapid Whole-Genome Sequencing (rWGS)

• Replacing "diagnostic odysseys" involving multiple, often invasive, tests
• Broadening and shortening the differential diagnosis
• Enabling earlier, targeted therapy instead of empirical, broad-spectrum treatment
• Reducing unnecessary invasive procedures

Newborn Genomic Screening

• The BEACONS program (launched in 2025 in the USA) is the first multi-state newborn genomic screening initiative backed by the NIH.
• A 2025 JAMA Network Open study (PMID 41105405 - Carli et al.) explored genomic sequencing approaches to newborn mass screening and its opportunities.
• The textbook notes NBS has grown from 5 conditions in 1995 to 35 core disorders today, with genomic platforms poised to expand this further. (Goldman-Cecil Medicine, p. 131)

n-of-1 Therapies

Mayo Clinic BabyFORce Program (2024-2025)

1. rWGS (standard practice in Mayo's NICU since June 2022)
2. Functional omics (transcriptomics, proteomics, metabolomics)
3. AI-driven drug repurposing - AI identifies FDA-approved drugs that could be repurposed to compensate for a patient's specific genetic variant, then tests them on the patient's own cells before clinical use

3. Artificial Intelligence in the Neonatal ICU

4. Pharmacogenomics

• Morphine: A 2026 retrospective NICU study (PMID 41478610 - Mankouski et al.) evaluated whether pharmacogenetics (CYP2D6, OPRM1 variants) can inform morphine dosing - a pressing question given frequent opioid use in NICU pain management.
• Vancomycin: Machine learning models using weight, gestational age, postnatal age, and serum creatinine now significantly outperform traditional dosing nomograms (PMID 37300630).
• Opioid withdrawal syndrome: Pharmacogenomic factors (including CYP2D6, UGT2B7 variants) influence severity of neonatal opioid withdrawal and respiratory risk PMID 37537419.

5. Multi-Omics Integration

• Transcriptomics: RNA expression profiling can validate pathogenicity of DNA variants and identify therapeutic targets (as in BabyFORce)
• Metabolomics: Identifies inborn errors of metabolism with high sensitivity; combined with rWGS, dramatically reduces time to diagnosis
• Proteomics: Protein-level biomarkers reflect real-time disease state, bridging the gap between genome and phenotype
• Microbiomics: The neonatal gut microbiome is highly plastic and influences immune development, infection risk, and necrotizing enterocolitis (NEC); microbiome modulation (probiotics, human milk, avoiding broad-spectrum antibiotics) is an emerging precision strategy

6. Precision Nutrition in the NICU

• Metabolomics and microbiome profiling guide human milk fortification strategies
• AI-driven nutritional guidance in ICUs is emerging (PMID 41285167)
• For inborn errors of metabolism (PKU, MSUD, organic acidemias), precision dietary restriction is literally life-saving and must be initiated in the neonatal period

7. Point-of-Care Diagnostics

• Targeted neonatal echocardiography: Non-invasive hemodynamic phenotyping to guide vasopressor choice, fluid therapy, PDA management
• Lung ultrasound: ESICM-ESPNIC 2025 consensus (PMID 40353867) supports quantitative lung ultrasound in intensive care
• POCUS applications: A 2024 systematic review (PMID 38929641) covers broad POCUS use in neonatology - cardiac, lung, brain, abdominal

8. Ethical, Equity, and Implementation Challenges

• Cost: Genomic sequencing remains expensive; payer coverage is inconsistent
• Genetics workforce gap: Shortage of clinical geneticists and genetic counselors for result interpretation
• Health equity: Access to rWGS is concentrated in academic centers; rural and low-income populations face barriers
• Data interpretation: Variants of uncertain significance (VUS) create diagnostic uncertainty
• Consent and ethics: Genomic data generated in the NICU may reveal secondary findings in parents; consent frameworks are still evolving
• Diverse population representation: Most genomic databases underrepresent non-European ancestries, reducing diagnostic yield in diverse populations

9. Global Perspective

Summary

1. Rapid genomic sequencing for diagnosis in hours, not months
2. AI for prediction, drug dosing individualization, and therapeutic identification
3. Multi-omics (transcriptomics, metabolomics, proteomics) bridging genotype to phenotype
4. Pharmacogenomics to individualize drug therapy
5. Point-of-care phenotyping (POCUS, TNE) for hemodynamic and respiratory precision
6. Precision nutrition informed by metabolomics and microbiome data
7. n-of-1 therapies as the ultimate expression of individualized care

Dissertations vs. Published Research in Precision Neonatal Medicine

1. Multi-Omics, AI & Precision Medicine - Foundational Reviews

Pammi M, Aghaeepour N, Neu J (2023)

Key finding: ML-integrated multiomics can identify disease risk before clinical signs, enabling early precision interventions.

Mohit, Verma S, Yadav A, Venkatesh V (2026)

2. Precision Diagnostics - Genomic Sequencing in the NICU

Marom D et al. (2024)

Wojcik MH et al. (2024)

Seither K, Thompson W, Suhrie K (2024)

Zheng J & Yang X (2025)

3. Precision Medicine for Neonatal Sepsis

Agudelo-Pérez SI, Molina-Castaño C, Quintero L (2021)

4. Precision Medicine for Bronchopulmonary Dysplasia (BPD)

Cheema Z, Kwinta P, Moreira A (2022)

5. Proteomics in Maternal and Neonatal Health

Elkahlout R et al. (2025)

6. Pharmacogenomics in the NICU

Mankouski A, Brunelli L, McMillin G (2026)

How to Find True Dissertations

• "precision medicine" AND "neonatal" AND "NICU"
• "whole genome sequencing" AND "newborn" AND "intensive care"
• "pharmacogenomics" AND "neonate"
• "neonatal sepsis" AND "omics"
• "bronchopulmonary dysplasia" AND "precision"